ASPIRA PATHLAB & DIAGNOSTICS | GLOBAL LONGLIFE | ASPIRA PATHLAB & DIAGNOSTICS / GLOBAL LONGLIFE |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -12.6 | - | - | View Chart |
P/BV | x | 2.4 | 0.7 | 350.6% | View Chart |
Dividend Yield | % | 0.0 | 0.0 | - |
ASPIRA PATHLAB & DIAGNOSTICS GLOBAL LONGLIFE |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ASPIRA PATHLAB & DIAGNOSTICS Mar-23 |
GLOBAL LONGLIFE Mar-23 |
ASPIRA PATHLAB & DIAGNOSTICS / GLOBAL LONGLIFE |
5-Yr Chart Click to enlarge
|
||
High | Rs | 75 | 141 | 53.2% | |
Low | Rs | 26 | 40 | 64.1% | |
Sales per share (Unadj.) | Rs | 14.0 | 22.4 | 62.8% | |
Earnings per share (Unadj.) | Rs | -0.1 | 1.7 | -5.0% | |
Cash flow per share (Unadj.) | Rs | 1.5 | 2.9 | 51.0% | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 12.4 | 61.2 | 20.2% | |
Shares outstanding (eoy) | m | 10.29 | 10.50 | 98.0% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.6 | 4.0 | 88.6% | |
Avg P/E ratio | x | -583.7 | 52.0 | -1,121.8% | |
P/CF ratio (eoy) | x | 34.6 | 31.8 | 109.0% | |
Price / Book Value ratio | x | 4.1 | 1.5 | 274.7% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 518 | 951 | 54.5% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 56 | 30 | 184.6% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 145 | 235 | 61.5% | |
Other income | Rs m | 3 | 2 | 134.3% | |
Total revenues | Rs m | 148 | 237 | 62.2% | |
Gross profit | Rs m | 16 | 41 | 39.2% | |
Depreciation | Rs m | 16 | 12 | 135.9% | |
Interest | Rs m | 4 | 4 | 96.5% | |
Profit before tax | Rs m | -1 | 27 | -3.3% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 0 | 9 | 0.0% | |
Profit after tax | Rs m | -1 | 18 | -4.9% | |
Gross profit margin | % | 11.0 | 17.3 | 63.7% | |
Effective tax rate | % | 0 | 32.5 | -0.0% | |
Net profit margin | % | -0.6 | 7.8 | -7.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 59 | 335 | 17.5% | |
Current liabilities | Rs m | 16 | 78 | 20.2% | |
Net working cap to sales | % | 29.5 | 109.3 | 27.0% | |
Current ratio | x | 3.7 | 4.3 | 86.4% | |
Inventory Days | Days | 88 | 315 | 27.8% | |
Debtors Days | Days | 590 | 1,506 | 39.2% | |
Net fixed assets | Rs m | 115 | 379 | 30.3% | |
Share capital | Rs m | 103 | 105 | 98.0% | |
"Free" reserves | Rs m | 25 | 538 | 4.6% | |
Net worth | Rs m | 128 | 643 | 19.8% | |
Long term debt | Rs m | 10 | 36 | 26.4% | |
Total assets | Rs m | 173 | 738 | 23.5% | |
Interest coverage | x | 0.8 | 7.3 | 10.9% | |
Debt to equity ratio | x | 0.1 | 0.1 | 133.2% | |
Sales to assets ratio | x | 0.8 | 0.3 | 261.8% | |
Return on assets | % | 1.9 | 3.1 | 61.9% | |
Return on equity | % | -0.7 | 2.8 | -24.5% | |
Return on capital | % | 2.4 | 4.6 | 51.8% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 0 | 0 | - | |
Fx outflow | Rs m | 0 | 0 | - | |
Net fx | Rs m | 0 | 0 | - |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 0 | -404 | 0.0% | |
From Investments | Rs m | 2 | -19 | -8.4% | |
From Financial Activity | Rs m | -9 | 457 | -2.0% | |
Net Cashflow | Rs m | -8 | 34 | -23.3% |
Indian Promoters | % | 18.7 | 54.3 | 34.5% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 0.0 | - | |
FIIs | % | 0.0 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 81.3 | 45.7 | 177.8% | |
Shareholders | 1,512 | 947 | 159.7% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ASPIRA PATHLAB & DIAGNOSTICS With: APOLLO HOSPITALS DR. LAL PATHLABS METROPOLIS HEALTHCARE KIMS NARAYANA HRUDAYALAYA
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | ASPIRA PATHLAB & DIAGNOSTICS | GLOBAL LONGLIFE | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | 4.98% | 4.72% | -0.08% |
1-Month | -1.20% | 0.96% | 0.53% |
1-Year | -11.42% | -12.34% | 50.88% |
3-Year CAGR | -1.76% | -32.35% | 13.33% |
5-Year CAGR | -4.03% | -20.90% | 21.12% |
* Compound Annual Growth Rate
Here are more details on the ASPIRA PATHLAB & DIAGNOSTICS share price and the GLOBAL LONGLIFE share price.
Moving on to shareholding structures...
The promoters of ASPIRA PATHLAB & DIAGNOSTICS hold a 18.7% stake in the company. In case of GLOBAL LONGLIFE the stake stands at 54.3%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of ASPIRA PATHLAB & DIAGNOSTICS and the shareholding pattern of GLOBAL LONGLIFE.
Finally, a word on dividends...
In the most recent financial year, ASPIRA PATHLAB & DIAGNOSTICS paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
GLOBAL LONGLIFE paid Rs 0.0, and its dividend payout ratio stood at 0.0%.
You may visit here to review the dividend history of ASPIRA PATHLAB & DIAGNOSTICS , and the dividend history of GLOBAL LONGLIFE.
For a sector overview, read our pharmaceuticals sector report.
After opening the day marginally higher, Indian share markets continued the momentum as the session progressed and ended the day higher.